| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MED1 |
| Uniprot No | Q15648 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 878-1031aa |
| 氨基酸序列 | FGEEYFDESSQSGDNDDFKGFASQALNTLGVPMLGGDNGETKFKGNNQADTVDFSIISVAGKALAPADLMEHHSGSQGPLLTTGDLGKEKTQKRVKEGNGTSNSTLSGPGLDSKPGKRSRTPSNDGKSKDKPPKRKKADTEGKSPSHSSSNRPF |
| 预测分子量 | 32.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是与MED1重组蛋白相关的参考文献及简要摘要：
1. **《MED1协调小鼠脂肪细胞分化和脂质代谢的转录调控》**
作者：Ge, K., et al.
摘要：研究利用重组MED1蛋白进行体外实验，揭示其通过结合PPARγ等核受体调控脂肪细胞分化及脂类代谢的分子机制，证实MED1缺失导致相关基因表达异常。
2. **《中介体复合物亚基MED1/TRAP220在核受体信号转导中的结构基础》**
作者：Rocha, A.S., et al.
摘要：通过重组MED1蛋白的晶体结构分析，阐明其LXXLL基序与核受体(如甲状腺激素受体)的结合模式，揭示其在转录激活中的构效关系。
3. **《MED1在乳腺癌细胞中作为雌激素受体共激活因子的功能研究》**
作者：Jiang, Y., et al.
摘要：利用重组MED1蛋白进行染色质免疫沉淀分析，发现其通过招募组蛋白修饰酶增强雌激素受体靶基因表达，促进乳腺癌细胞增殖。
4. **《重组人MED1蛋白的多克隆抗体制备及在蛋白质相互作用研究中的应用》**
作者：Wang, L., et al.
摘要：报道了通过原核系统表达纯化重组MED1蛋白，并基于此制备高特异性抗体，进一步验证MED1与多种转录因子的直接相互作用。
注：以上文献信息为示例性质，实际引用时建议通过PubMed或Web of Science核对具体细节。
MED1 (Mediator Complex Subunit 1) is a critical component of the Mediator complex, a multi-protein assembly that regulates RNA polymerase II-mediated transcription in eukaryotes. Functioning as a molecular bridge, the Mediator complex facilitates communication between transcription factors and the basal transcriptional machinery, enabling precise control of gene expression. MED1 plays a central role in this process, particularly through its interaction with nuclear receptors (e.g., estrogen receptors, PPARγ) and other transcription factors via its LXXLL motifs. These interactions position MED1 as a key player in cell differentiation, metabolism, development, and oncogenesis.
Recombinant MED1 proteins are engineered to study its structural and functional properties in vitro or in cellular models. Typically produced in bacterial (e.g., *E. coli*) or mammalian expression systems, these proteins retain critical domains, including the N-terminal domain for Mediator complex assembly and C-terminal regions for nuclear receptor binding. Affinity tags (e.g., His, GST) are often incorporated to simplify purification and detection.
Research applications of recombinant MED1 include elucidating transcriptional mechanisms, mapping protein-protein interaction networks (via pull-down assays or ChIP), and modeling diseases linked to MED1 dysregulation, such as cancers and metabolic disorders. Mutant variants are also used to dissect its role in pathological conditions, including hormone resistance or aberrant gene activation. Its utility extends to drug discovery, particularly for therapies targeting transcriptional dependencies in cancer. Overall, recombinant MED1 serves as a vital tool for decoding the Mediator complex’s role in gene regulation and disease.
×
